{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:53:55Z","timestamp":1794020035882,"version":"4.8.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106860h0001"],"award-info":[{"award-number":["23ck0106860h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.leukres.2025.107653","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T19:19:35Z","timestamp":1736968775000},"page":"107653","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia\/lymphoma"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5935-0385","authenticated-orcid":false,"given":"Makoto","family":"Yoshimitsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2025.107653_bib1","doi-asserted-by":"crossref","first-page":"e517","DOI":"10.1016\/S1470-2045(14)70202-5","article-title":"Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma","volume":"15","author":"Ishitsuka","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2025.107653_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15097","article-title":"Epidemiology of adult T-cell leukemia-lymphoma in Japan: an updated analysis, 2012-2013","author":"Ito","year":"2021","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.leukres.2025.107653_bib3","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2025.107653_bib4","series-title":"Adult T-cell Leukaemia.","first-page":"221","article-title":"Chemotherapy of ATL","author":"Shimoyama","year":"1994"},{"issue":"34","key":"10.1016\/j.leukres.2025.107653_bib5","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.leukres.2025.107653_bib6","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1111\/cas.14658","article-title":"Prognosis of patients with adult T-cell leukemia\/lymphoma in Japan: a nationwide hospital-based study","volume":"111","author":"Imaizumi","year":"2020","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.leukres.2025.107653_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2025.107653_bib8","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1172\/JCI111379","article-title":"Functional and phenotypic comparison of human T cell leukemia\/lymphoma virus positive adult T cell leukemia with human T cell leukemia\/lymphoma virus negative S\u00e9zary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the huma","volume":"73","author":"Waldmann","year":"1984","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib9","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","article-title":"Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2","volume":"72","author":"Waldmann","year":"1988","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2025.107653_bib10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V82.6.1701.1701","article-title":"The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia","volume":"82","author":"Waldmann","year":"1993","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib11","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.clim.2014.09.012","article-title":"Safety, efficacy, and pharmacokinetics\/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia\/lymphoma","volume":"155","author":"Berkowitz","year":"2014","journal-title":"Clin. Immunol."},{"issue":"11","key":"10.1016\/j.leukres.2025.107653_bib12","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063","article-title":"Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac","volume":"86","author":"Waldmann","year":"1995","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-15-1412","article-title":"Complete remissions of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 and chemotherapy to block immunogenicity","volume":"22","author":"Kreitman","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2009.07606.x","article-title":"Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy","volume":"145","author":"Jiang","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.leukres.2025.107653_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1158\/1078-0432.CCR-16-1022","article-title":"Phase II study of alemtuzumab (CAMPATH-1) in patients with HTLV-1-associated adult T-cell leukemia\/lymphoma","volume":"23","author":"Sharma","year":"2017","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2025.107653_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int. Immunol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib17","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood.V99.5.1505","article-title":"Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells","volume":"99","author":"Yoshie","year":"2002","journal-title":"Blood"},{"issue":"10 Pt 1","key":"10.1016\/j.leukres.2025.107653_bib18","first-page":"3625","article-title":"Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome","volume":"9","author":"Ishida","year":"2003","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"30","key":"10.1016\/j.leukres.2025.107653_bib19","doi-asserted-by":"crossref","first-page":"26733","DOI":"10.1074\/jbc.M202069200","article-title":"Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity","volume":"277","author":"Shields","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.leukres.2025.107653_bib20","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1158\/1078-0432.CCR-04-2263","article-title":"Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density","volume":"11","author":"Niwa","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.leukres.2025.107653_bib21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1158\/0008-5472.CAN-03-2068","article-title":"Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma","volume":"64","author":"Niwa","year":"2004","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.leukres.2025.107653_bib22","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1158\/1078-0432.CCR-04-0983","article-title":"The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia\/lymphoma","volume":"10","author":"Ishida","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib23","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.leukres.2025.107653_bib24","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00262-008-0632-0","article-title":"Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD\/Shi-scid, IL-2Rgamma(null) mouse model","volume":"58","author":"Ito","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.leukres.2025.107653_bib25","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.4049\/jimmunol.0900699","article-title":"Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD\/Shi-scid, IL-2R gamma(null) mice in vivo","volume":"183","author":"Ito","year":"2009","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107653_bib26","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2025.107653_bib27","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib28","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.leukres.2025.107653_bib29","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15123","article-title":"Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation","volume":"184","author":"Ishida","year":"2019","journal-title":"Br. J. Haematol."},{"issue":"28","key":"10.1016\/j.leukres.2025.107653_bib30","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 Antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"44","key":"10.1016\/j.leukres.2025.107653_bib31","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+\u202fregulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"19","key":"10.1016\/j.leukres.2025.107653_bib32","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by Mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib34","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson Syndrome associated with mogamulizumab treatment of adult T-cell leukemia \/ lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.leukres.2025.107653_bib35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2326-6066.CIR-15-0303","article-title":"Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia","volume":"4","author":"Ureshino","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.leukres.2025.107653_bib36","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/bjh.18281","article-title":"Beneficial impact of first-line mogamulizumab-containing chemotherapy in adult T-cell leukaemia-lymphoma","volume":"198","author":"Shichijo","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"13","key":"10.1016\/j.leukres.2025.107653_bib37","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1084\/jem.20140987","article-title":"Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma","volume":"211","author":"Nakagawa","year":"2014","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/path.4699","article-title":"CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia\/lymphoma with poor prognosis","volume":"238","author":"Yoshida","year":"2016","journal-title":"J. Pathol."},{"issue":"7","key":"10.1016\/j.leukres.2025.107653_bib39","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.2021013568","article-title":"Whole-genome landscape of adult T-cell leukemia\/lymphoma","volume":"139","author":"Kogure","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.107653_bib40","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2025.107653_bib41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/hon.3072","article-title":"CCR7 alterations associated with inferior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"40","author":"Sakamoto","year":"2022","journal-title":"Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2025.107653_bib42","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.3324\/haematol.2021.280352","article-title":"Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia\/lymphoma","volume":"107","author":"Tanaka","year":"2022","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.leukres.2025.107653_bib43","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia-lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.leukres.2025.107653_bib44","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/bjh.14634","article-title":"Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma","volume":"181","author":"Tokunaga","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"14","key":"10.1016\/j.leukres.2025.107653_bib45","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1158\/1078-0432.CCR-18-2575","article-title":"Mogamulizumab treatment elicits autoantibodies attacking the skin in patients with adult T-cell leukemia-lymphoma","volume":"25","author":"Suzuki","year":"2019","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2025.107653_bib46","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1182\/bloodadvances.2020001641","article-title":"Robust CD8+ T-cell proliferation and diversification after mogamulizumab in patients with adult T-cell leukemia-lymphoma","volume":"4","author":"Saito","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.leukres.2025.107653_bib47","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hon.2242","article-title":"Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T-cell leukaemia\/lymphoma","volume":"35","author":"Shiratori","year":"2017","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib48","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","article-title":"Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases","volume":"58","author":"Karube","year":"2008","journal-title":"Pathol. Int."},{"issue":"8","key":"10.1016\/j.leukres.2025.107653_bib49","article-title":"A comprehensive study of the immunophenotype and its clinicopathologic significance in adult T-cell leukemia\/lymphoma","volume":"36","author":"Tamaki","year":"2023","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"issue":"10168","key":"10.1016\/j.leukres.2025.107653_bib50","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.leukres.2025.107653_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/bjh.15152","article-title":"Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party","volume":"181","author":"Bazarbachi","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.leukres.2025.107653_bib52","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood-2011-07-368233","article-title":"Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study","volume":"119","author":"Kanda","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2025.107653_bib53","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.13302","article-title":"Clinical outcomes of a novel therapeutic vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia\/lymphoma in a pilot study","volume":"169","author":"Suehiro","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.leukres.2025.107653_bib54","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/leu.2008.272","article-title":"PD-1\/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia\/lymphoma patients","volume":"23","author":"Kozako","year":"2009","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.leukres.2025.107653_bib55","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","article-title":"PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma","volume":"128","author":"Miyoshi","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.leukres.2025.107653_bib56","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.leukres.2025.107653_bib57","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.2019002038","article-title":"Rapid progression of adult T-cell leukemia\/lymphoma as tumor-infiltrating Tregs after PD-1 blockade","volume":"134","author":"Rauch","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2025.107653_bib58","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1056\/NEJMc1807852","article-title":"PD-1 inhibitor therapy in adult T-Cell leukemia\u2013lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"7683","key":"10.1016\/j.leukres.2025.107653_bib59","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature24649","article-title":"PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis","volume":"552","author":"Wartewig","year":"2017","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.leukres.2025.107653_bib60","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.cell.2021.05.027","article-title":"Expansion of tumor-associated Treg cells upon disruption of a CTLA-4-dependent feedback loop","volume":"184","author":"Marangoni","year":"2021","journal-title":"Cell"},{"issue":"13","key":"10.1016\/j.leukres.2025.107653_bib61","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood.2023022204","article-title":"Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas","volume":"143","author":"Hill","year":"2024","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2025.107653_bib62","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1182\/bloodadvances.2022008327","article-title":"Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma","volume":"7","author":"Watanabe","year":"2023","journal-title":"Blood Adv."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500013X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262500013X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T09:57:33Z","timestamp":1740391053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262500013X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":62,"alternative-id":["S014521262500013X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107653","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted antibody therapy as a treatment strategy for aggressive adult T-cell leukemia\/lymphoma","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107653","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107653"}}